How does Evrysdi (risdiplam) treat spinal muscular atrophy (SMA)?
Evrysdi (risdiplam) treats SMA by increasing production of the SMN (survival motor neuron) protein, which is the key missing factor in the disease. In SMA, low SMN protein levels lead to loss of motor neurons and progressive muscle weakness. Risdiplam is designed to act on the SMN2 gene so it produces more full-length, functional SMN protein, helping support motor neuron survival and improving strength and function.
What does risdiplam do at the gene/molecular level?
Risdiplam works by modifying how the SMN2 gene is processed (spliced) so that more of the messenger RNA makes the full-length SMN protein rather than a shorter, less effective form. By shifting this RNA splicing outcome toward functional SMN production, Evrysdi raises SMN protein levels in the body, which addresses the underlying biology of SMA rather than just symptoms.
How is this different from other SMA treatments?
Evrysdi is an oral medication that increases SMN protein production through effects on SMN2 splicing. Other major SMA approaches include:
- Gene therapy (for some patients): delivers a functional copy of SMN1 to make SMN protein production possible from the delivered gene.
- Antisense therapies: also target SMN2 splicing, but with different mechanisms and delivery methods.
These differences matter for administration (oral vs. injected) and for how quickly each therapy can affect SMN levels, though exact timing depends on the product and patient factors.
How quickly should patients expect to see effects?
Because SMA progresses over time and SMN levels can rise soon after treatment starts, improvements may show up as gained or stabilized motor milestones rather than a single immediate change. The pattern of response varies by age at treatment and baseline severity, since earlier treatment generally offers a better chance to preserve motor neurons before they are lost.
What patients and caregivers usually monitor while on Evrysdi?
Clinicians typically track changes in motor function and milestones, respiratory and bulbar symptoms (swallowing/breathing issues), growth/nutrition, and overall tolerability. As with any chronic SMA therapy, ongoing follow-up is used to confirm that the medication is helping and to adjust supportive care if needed.
Sources
No sources were provided in your prompt, so I can’t cite specific documents or label information here. If you share the source text you want used (or allow me to search), I can add precise, cited details on mechanism and clinical expectations.